8-K Announcements
6Nov 17, 2026·SEC
Nov 16, 2026·SEC
Nov 13, 2026·SEC
DataMEDS AI's reported revenue has been volatile, falling from $12.4M in 2024Q4 to $1.6M in 2026Q1 and showing no durable base, while operating losses appeared in every quarter reviewed.
Price trend, volume and key moving averages
Trailing total returns as of 11/20/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 13, 2026 | $2.72 vs — | $3M vs — |
Q3 2026 Aug 17, 2026 | -$3.26 vs — | $2M vs — |
Q2 2026 May 19, 2026 | -$3.50 vs — | $2M vs — |
Q2 2026 Mar 20, 2026 | -$6.50 vs — | $2M vs — |
Benchmark MEDS against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for DataMEDS AI, Inc. (MEDS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.73 | $2.88M | -0.07 | 28.73% | -564.77% | — | — | |
| $84.80 | $9.66B | 22.67 | 4.03% | 3.07% | 8.83% | — | |
| $0.02 | $1.48M | -0.00 | -74.19% | -6.72% | — | — | |
| $24.77 | $1.7B | 16.39 | 7.08% | 5.58% | 20.22% | — | |
| $1062.16 | $123.95B | 26.37 | 12.36% | 1.12% | — | 0.29% | |
| $272.34 | $63.78B | 34.90 | 14.23% | 0.71% | — | 0.76% |
DataMEDS AI, Inc. (MEDS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
DataMEDS AI, Inc. (MEDS) SEC filings — annual & quarterly reports (10-K, 10-Q)
Nov 17, 2026·SEC
Nov 16, 2026·SEC
Nov 13, 2026·SEC
Mar 20, 2026·SEC
Get notified when MEDS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
DataMEDS AI, Inc. (MEDS) stock FAQ — growth, dividends, profitability & financials explained
DataMEDS AI, Inc. (MEDS) reported $7.7M in revenue over the trailing twelve months. Revenue was $23.3M in fiscal year 2025.
DataMEDS AI, Inc. (MEDS) revenue fell by 77.5% over the trailing twelve months, compared with the twelve months before.
No. DataMEDS AI, Inc. (MEDS) reported a net loss of $43.4M over the trailing twelve months.
DataMEDS AI, Inc. (MEDS) had negative free cash flow of $15.8M over the trailing twelve months.